Psychedelic Therapy FDA
![Psychedelic Therapy FDA](/upload/7257360/e1ab53b2ef314e1786bed1d8639870cb--0--63bdf331bfeb4176a67d105f9c008d1f.jpg?w=1000&original=)
Psychedelic Therapy FDA
FILE - In this photo made with a long exposure, a man is silhouetted against lights reflected in the waters off Cape Neddick in Maine on Dec. 11, 2017. Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. The advisers to the Food and Drug Administration are scheduled to vote on the drug's safety and effectiveness Tuesday, June 4, 2024, potentially setting the stage for federal approval later this year. (AP Photo/Robert F. Bukaty, File)
Абонирайте се
Влезте във Вашата БТА
Избиране на снимки
Моля потвърдете избраните снимки. Това действие не е свързано с плащане. Ако продължите, избраните снимки ще бъдат извадени от баланса на вашите активни абонаментни пакети.
Изтегляне на снимка
Моля потвърдете изтеглянето на снимката/ите
![Psychedelic Therapy FDA](/upload/7257360/e1ab53b2ef314e1786bed1d8639870cb--0--63bdf331bfeb4176a67d105f9c008d1f.jpg?w=270&h=180)
FILE - In this photo made with a long exposure, a man is silhouetted against lights reflected in the waters off Cape Neddick in Maine on Dec. 11, 2017. Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. The advisers to the Food and Drug Administration are scheduled to vote on the drug's safety and effectiveness Tuesday, June 4, 2024, potentially setting the stage for federal approval later this year. (AP Photo/Robert F. Bukaty, File)